BIA comment on Government response to the Health Committee’s report on Brexit and medicines, medical devices and substances of human origin
BIA CEO Steve Bates said: “This response shows that the government understands the complexities Brexit has brought to getting medicines to NHS patients, however it does not provide the detailed answers needed for the sector to plan with clarity. Our priority remains ensuring that NHS patients continue to receive their medicines both day 1 post-Brexit and in the future. There are measures the UK government can take unilaterally to increase certainty for our sector as they work to ensure that they can continue to supply medicines to patients, and I strongly encourage them to do so immediately.”
Media enquiries: Ed Sexton: email@example.com 0207 6302196
About the BIA
Established over 25 years ago at the infancy of biotechnology, the BioIndustry Association (BIA) is the trade association for innovative enterprises involved in UK bioscience. Members include emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector. The BIA represents the interests of its members to a broad section of stakeholders, from government and regulators to patient groups and the media. Our goal is to secure the UK's position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people's lives.